SULFAMETHOXAZOLE Drug Patent Profile
✉ Email this page to a colleague
When do Sulfamethoxazole patents expire, and what generic alternatives are available?
Sulfamethoxazole is a drug marketed by Ascot, Barr, Heather, Rising, Watson Labs, Abraxis Pharm, Bedford, Hikma, Hospira, Mylan Labs Ltd, Somerset, Teva Pharms Usa, Ani Pharms, Aurobindo Pharma, Chartwell Molecular, Lupin Ltd, Novitium Pharma, Prasco, Teva, Amneal Pharms Ny, Chartwell Molecules, Fosun Pharma, Glenmark Generics, Interpharm, Martec Usa Llc, Mutual Pharm, Pliva, Roxane, Sun Pharm Industries, Usl Pharma, Vista Pharms, Able, and Heritage Pharma Avet. and is included in fifty-three NDAs.
The generic ingredient in SULFAMETHOXAZOLE is phenazopyridine hydrochloride; sulfamethoxazole; trimethoprim. There are eight drug master file entries for this compound. Additional details are available on the phenazopyridine hydrochloride; sulfamethoxazole; trimethoprim profile page.
Summary for SULFAMETHOXAZOLE
US Patents: | 0 |
Applicants: | 33 |
NDAs: | 53 |
Raw Ingredient (Bulk) Api Vendors: | 161 |
Clinical Trials: | 157 |
Patent Applications: | 4,101 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SULFAMETHOXAZOLE |
DailyMed Link: | SULFAMETHOXAZOLE at DailyMed |
Recent Clinical Trials for SULFAMETHOXAZOLE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Johns Hopkins University | Early Phase 1 |
The Cleveland Clinic | Phase 4 |
Assistance Publique - Hôpitaux de Paris | Phase 4 |